Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer
{{output}}
Importance: The US Food and Drug Administration approved immune checkpoint inhibitors (immunotherapy) for select cases of head and neck squamous cell carcinoma (HNSCC) in 2016. However, it is unclear whether there are clinical or... ...
